02-06-2021 | 14:57

Participants of the forum "Medicine Safety" tried to go further into the issue of what prevents the launch of pilot projects on medicine reimbursement

Timofey Nizhegorodtsev, the Deputy Head of the FAS Russia, presented to the participants of the session entitled "The system of medicine provision: increasing affordability of medicines" analysis of possible models of medicine reimbursement on the example of the program of medicine reimbursement for citizens suffering from acute cardiovascular diseases. We are talking about medicine provision of patients at the lowest price of the register, at the median price of the register, as well as through a copayment according to different models.

"Despite the fact that we conducted a comparative analysis at the beginning of 2020, as well as completed revision of prices for vital medicines, it retains the basic contours and previously made conclusions," Timofey Nizhegorodtsev said.

In a comparative analysis of the reimbursement models, the antimonopoly service identified their common risks. First is the use of unreliable and outdated statistics on the real need of patients for medicines.

"Calculations should be made according to a conservative scenario and based on the actual number of patients. Provision should also be made for the possibility of introducing coefficients in case of an increase in the number of patients in the program. Now, the calculations provided in various presentations are not properly verified, which means that they create risks of a program deficit in budgetary terms," explained the Deputy Head of the FAS of Russia.

Different models of medicine reimbursement assume different effects in terms of achieving the purposes of the medicine reimbursement system itself.
The first model provides for 100% free medicine provision of patients, the procurement of which will be carried out at the lowest price of the register. However, its use carries the risks of defects and constant monitoring of the volume of production of medicines in this price category.

The second model also assumes free medicines provision of patients, including original expensive ones, but already at the median price of the register. The definitive advantages of this model are the minimization of the risk of defects due to the expansion of the number of pharmaceutical producers participating in the program and, as a result, the medicine assortment for patients and the wholesalers, as well as the availability of medicine therapy in general, while maintaining the possibility of choosing medicines.

The third model is copayment, when the state reimburses 50% of the price of the medicine.

"Many people consider this model to be the most compelling. However, calculations show that the purposes of medicine reimbursement may not be achieved," said the Deputy Head of the FAS Russia.

In conclusion, Timofey Nizhegorodtsev noted "our main task is to combine these three models with the goals of medicine reimbursement and carry out a pilot project."

However, to implement the pilot projects on medicine reimbursement, a number of conditions should be fulfilled:

• develop and approve the regulatory framework at the federal and regional levels;

• conduct a conservative assessment of patient coverage (based on actual need) and related budgets (without reduction);

• consider the possibility of introducing a copayment system, that would exclude the possibility of promoting specific medicine brands of individual producers;

• develop single for all regions reference points of the effectiveness of implementation of pilot projects;

• conduct a pilot project in a small number of regions, simultaneously throughout the region.

At the same time, the participants of the pilot project must ensure:

• availability of a developed information system (a system for issuing and moving electronic prescriptions);

• guarantees of regional budgets in case of a shortage of allocated funds from the federal budget;

• prompt adoption of the regional regulatory framework for launching the pilot project.

Site Map

News & Events Press Releases Media Releases Image Library About the FAS Russia What We Do General Information Mission, Goals, Values Priority Setting Institutional Memory Stakeholders Engagement Center for Education and Methodics Our History Our Structure Powers of Head and Deputy Heads Our Ratings GCR Using our website International Cooperation Treaties & Agreements OECD Competition Committee OECD meetings 2013 OECD meetings 2014 OECD meetings 2015 OECD meetings 2016 OECD meetings 2017 OECD meetings 2018 OECD meetings 2019 OECD meetings 2020 FAS Annual Reports OECD-GVH RCC RCC Newsletter ICAP Council on Advertising Headquarters for Joint Investigations UNCTAD 13th session IGE UNCTAD Resolution Russian contributions 14th session IGE UNCTAD Resolution Russian contributions 15th session IGE UNCTAD 16th session IGE UNCTAD 17th session IGE UNCTAD 18th session IGE UNCTAD 8th UN Conference on Competition EEU Model Law on Competition ICN BRICS BRICS Conferences Documents The BRICS Competition Law and Policy Centre (BRICS Competition Centre) BRICS Working Groups for the research of competition issues in socially important markets The Working Group for Research on the Competition Issues in the Pharmaceutical Markets Chair: Russia The Working Group for Research on food value chains Chair: South Africa The Working Group for Research on the Competition Issues in the Automobile Markets Co-chaired: India, South Africa The Working Group for Research on the Competition Issues in the Digital Markets Co-chairs: Brazil, Russia BRICS Coordination Committee on antimonopoly policy EU APEC Competition Policy and Law Group Annual meetings Projects ERRA Full Members Organizational Structure Archive Working Group on Investigating Issues on Pricing in the Oil and Oil Product Markets and Methods of their Functioning Meetings Working Group for Studying Competition Problems in the Pharmaceutical Sector Working Group on Research of Competition Issues in the Market of International Telecommunications (Roaming) Document Library Legislation Reports & Analytics Cases & decisions Contacts Give feedback Contact us Links Authorities Worldwide COVID-19